Study identifier:D5130C00079
ClinicalTrials.gov identifier:NCT01744288
EudraCT identifier:N/A
CTIS identifier:N/A
A open label, randomized, crossover and potential parallel, single dose study of ticagrelor 180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo platelet transfusion to determine the effects of platelet supplementation on the reversibility of platelet inhibition
Inhibition on Platelet aggregation
Phase 1
Yes
Ticagrelor, Clopidogrel, ASA
All
258
Interventional
18 Years - 50 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
A open label, randomized, crossover and potential parallel, single dose study of ticagrelor 180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo platelet transfusion to determine the effects of platelet supplementation on the reversibility of platelet inhibition
Location
Location
Overland Park, KS, United States
Arms | Assigned Interventions |
---|---|
Experimental: 1 Ticagrelor with Platelet transfusion | Drug: Ticagrelor Oral single loading dose 180ng Drug: ASA 81mg once daily from day -2 up to platelet transfusion |
Experimental: 2 Ticagrelor without Platelet transfusion | Drug: Ticagrelor Oral single loading dose 180ng Drug: ASA 81mg once daily from day -2 up to platelet transfusion |
Active Comparator: 3 Clopidogrel with Platelet transfusion | Drug: Clopidogrel Oral single loading dose 600mg Drug: ASA 81mg once daily from day -2 up to platelet transfusion |
Active Comparator: 4 Clopidogrel without Platelet transfusion | Drug: Clopidogrel Oral single loading dose 600mg Drug: ASA 81mg once daily from day -2 up to platelet transfusion |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.